Source comparison
Best Sermorelin Dosage Skin Elasticity 2026: Comparison with Alternatives
Sermorelin (GRF 1-29) GHRH receptor agonist. Amplifies endogenous GH pulse 200–300mcg nightly Indirect via IGF-1 upregulation in fibroblasts 8–10 minutes Best option for preserving natural GH feedback; requires nightly dosing due to short half-life; circadian
This comparison does not assign a generated winner or score.
- Sermorelin (GRF 1-29)
- GHRH receptor agonist. Amplifies endogenous GH pulse
- 200–300mcg nightly
- Indirect via IGF-1 upregulation in fibroblasts
- 8–10 minutes
- Best option for preserving natural GH feedback; requires nightly dosing due to short half-life; circadian timing critical
- CJC-1295 (DAC)
- Long-acting GHRH analogue with drug affinity complex
- 1–2mg twice weekly
- Indirect via sustained IGF-1 elevation
- 6–8 days
- Longer dosing interval but higher risk of supraphysiological GH spikes; less circadian alignment; not ideal for first-time users
- GHK-Cu (copper peptide)
- Direct fibroblast activation and metalloproteinase modulation
- Topical 1–2% or 1–3mg subcutaneous
- Direct collagen gene transcription and TGF-β signaling
- 30 minutes (systemic)
- Works through different pathway than GH; can be combined with Sermorelin; topical formulations have low bioavailability
- BPC-157
- Angiogenesis and extracellular matrix repair signaling
- 250–500mcg daily
- Indirect via VEGF upregulation and fibroblast migration
- 4 hours
- Primarily wound healing and tissue repair. Not GH-mediated; limited evidence for cosmetic skin elasticity improvements
- Exogenous GH (somatropin)
- Direct GH replacement
- 0.5–2 IU daily
- Direct IGF-1 elevation without pulsatility
- 3–4 hours
- Bypasses natural feedback; higher side effect risk (insulin resistance, edema); significantly more expensive; requires prescription
- Sermorelin's advantage for skin elasticity is its preservation of physiological GH pulsatility. The body still regulates secretion through negative feedback, preventing the insulin resistance and glucose dysregulation seen with chronic exogenous GH use. CJC-1295 with DAC extends the half-life to nearly a week, allowing twice-weekly dosing instead of nightly injections, but the trade-off is loss of circadian alignment and higher trough GH levels that can desensitize receptors over time. For skin-specific outcomes, the nightly pulsatile approach with Sermorelin consistently outperforms sustained elevation protocols in long-term user reports.